Pfizer (NYSE:PFE) Trading Up 0.3% – Should You Buy?

Pfizer Inc. (NYSE:PFE) shares shot up 0.3% on Wednesday . The company traded as high as $25.63 and last traded at $25.63. 9,270,671 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 36,584,264 shares. The stock had previously closed at $25.55.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. UBS Group dropped their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

The company’s 50-day moving average is $26.09 and its 200-day moving average is $26.97. The firm has a market capitalization of $142.93 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC grew its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the fourth quarter valued at about $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.